31![Spring Seminars 2009 Cellular therapies: insights and new horizons 16 & 17 April 2009 Amsterdam, The Netherlands Royal Tropical Institute, Amsterdam, The Netherlands Spring Seminars 2009 Cellular therapies: insights and new horizons 16 & 17 April 2009 Amsterdam, The Netherlands Royal Tropical Institute, Amsterdam, The Netherlands](https://www.pdfsearch.io/img/f3fd8c74244f0de20a0f8e223300cabd.jpg) | Add to Reading ListSource URL: www.sanquin.nlLanguage: English - Date: 2014-10-06 07:31:27
|
---|
32![Microsoft PowerPoint - AM0010-001 TIP Mayfinal Microsoft PowerPoint - AM0010-001 TIP Mayfinal](https://www.pdfsearch.io/img/501efabe1e9065e8eedaef15f6e7637f.jpg) | Add to Reading ListSource URL: www.armobio.comLanguage: English - Date: 2015-12-11 00:15:27
|
---|
33![ISCT NA 2016 Abstract Categories Stem Cells including but not limited to: Hematopoietic Mesenchymal iPSC Tissue specific ISCT NA 2016 Abstract Categories Stem Cells including but not limited to: Hematopoietic Mesenchymal iPSC Tissue specific](https://www.pdfsearch.io/img/39a4742738775619a42f61171c922428.jpg) | Add to Reading ListSource URL: www.isct-na2016.comLanguage: English - Date: 2016-02-19 14:43:52
|
---|
34![12th International Workshop IMMUNOTHERAPY 2016: “Mapping the road for a long lasting immune-mediated control of cancer” 12th International Workshop IMMUNOTHERAPY 2016: “Mapping the road for a long lasting immune-mediated control of cancer”](https://www.pdfsearch.io/img/ffd6cd68c13561d010c3fb795d066097.jpg) | Add to Reading ListSource URL: www.immunotherapy.cim.co.cuLanguage: English - Date: 2015-12-17 09:23:28
|
---|
35![VAXIMM Appoints Pharmaceutical Industry Veteran Dr. Jarl Ulf Jungnelius as Chief Medical Officer Basel (Switzerland) and Mannheim (Germany), May 18, 2016 – VAXIMM AG, a Swiss-German biotech company focused on developin VAXIMM Appoints Pharmaceutical Industry Veteran Dr. Jarl Ulf Jungnelius as Chief Medical Officer Basel (Switzerland) and Mannheim (Germany), May 18, 2016 – VAXIMM AG, a Swiss-German biotech company focused on developin](https://www.pdfsearch.io/img/f41b2986d36a88593986a10957f5060f.jpg) | Add to Reading ListSource URL: www.biomedvc.comLanguage: English - Date: 2016-05-18 04:29:39
|
---|
36![PRESS RELEASE – IMMUNOCORE LIMITED Immunocore Presents Positive IMCgp100 Phase I Data at the 2016 ASCO Annual Meeting - PRESS RELEASE – IMMUNOCORE LIMITED Immunocore Presents Positive IMCgp100 Phase I Data at the 2016 ASCO Annual Meeting -](https://www.pdfsearch.io/img/e8de4d2eb0362ef9f25c8b5c053020fe.jpg) | Add to Reading ListSource URL: www.immunocore.comLanguage: English - Date: 2016-06-06 05:18:35
|
---|
37![Safety and Tolerability of Escalating Doses of House Dust Mite- Peptide Antigen Desensitization (HDM-PAD) Safety and Tolerability of Escalating Doses of House Dust Mite- Peptide Antigen Desensitization (HDM-PAD)](https://www.pdfsearch.io/img/47058d6cf1875cc1fed5dc2027f90488.jpg) | Add to Reading ListSource URL: www.circassia.comLanguage: English - Date: 2015-11-05 09:21:27
|
---|
38![Press Release GANYMED ANNOUNCES LICENSE OF WT1 IMMUNOTHERAPY RIGHTS BY CORIXA AND KIRIN Mainz, Germany / June 08, 2004 Ganymed Pharmaceuticals AG, Mainz, Germany, announced today that Corixa Corporation (Nasdaq: CRXA), U Press Release GANYMED ANNOUNCES LICENSE OF WT1 IMMUNOTHERAPY RIGHTS BY CORIXA AND KIRIN Mainz, Germany / June 08, 2004 Ganymed Pharmaceuticals AG, Mainz, Germany, announced today that Corixa Corporation (Nasdaq: CRXA), U](https://www.pdfsearch.io/img/11717774fff5ce9db4eedbed9c5ec758.jpg) | Add to Reading ListSource URL: www.ganymed-pharmaceuticals.comLanguage: English - Date: 2015-02-04 05:14:56
|
---|
39![ASCO Annual Meeting - Chicago, IL, May 29 –June 2, 2015; Abstract #3017 Poster #: 343 A first-in-human dose escalation study of PEGylated recombinant human IL-10 (AM0010) in advanced solid tumors. Jeffrey R. Infante1, ASCO Annual Meeting - Chicago, IL, May 29 –June 2, 2015; Abstract #3017 Poster #: 343 A first-in-human dose escalation study of PEGylated recombinant human IL-10 (AM0010) in advanced solid tumors. Jeffrey R. Infante1,](https://www.pdfsearch.io/img/347d9696640c41a78a4096aca0d08818.jpg) | Add to Reading ListSource URL: www.armobio.comLanguage: English - Date: 2015-12-11 00:15:33
|
---|
40![IMMUNOTHERAPIES MOVING FORWARD COMPANY Agilvax is a biotechnology company developing targeted cancer stem cell immunotherapies and vaccines for infectious diseases. The company’s IMMUNOTHERAPIES MOVING FORWARD COMPANY Agilvax is a biotechnology company developing targeted cancer stem cell immunotherapies and vaccines for infectious diseases. The company’s](https://www.pdfsearch.io/img/058d9ffbf41d946ab365ef54421b1587.jpg) | Add to Reading ListSource URL: agilvax.comLanguage: English - Date: 2016-07-25 22:36:40
|
---|